X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the advancement of the Company’s pipeline through multiple stages of clinical development, including ENX-102, a next-generation, precision-targeted GABAA positive allosteric modulator (PAM) for the treatment of generalized anxiety disorder.
Lead Product(s): ENX-102
Therapeutic Area: Psychiatry/Psychology Product Name: ENX-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F-Prime Capital
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 19, 2024
Details:
ENX-102 is an investigational subtype-selective GABA-A PAM acting to enhance GABA neurotransmission in receptors containing the α2, α3, and α5 subunits while blocking α1, which is investigated for Generalized Anxiety Disorder.
Lead Product(s): ENX-102
Therapeutic Area: Psychiatry/Psychology Product Name: ENX-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
ENX-101, administered orally once daily for ten days, was safe and well tolerated in healthy volunteers. There were no dose-related, clinically meaningful changes in vital signs, electrocardiograms, physical exams, or clinical laboratory values.
Lead Product(s): ENX-101
Therapeutic Area: Neurology Product Name: ENX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The deal grants Engrail rights to intellectual property for the use of elesclomol. Engrail explore the potential of elesclomol-copper to significantly alter the course of mortality and morbidity for Mitochondrial copper metabolism disorders.
Lead Product(s): Elesclomol
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: The Texas A&M University System
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 08, 2021
Details:
The Company will use the proceeds to finance the advancement of their diverse pipeline, including its lead assets, ENX-101, ENX-102 and internal preclinical programs. Engrail’s lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles.
Lead Product(s): ENX-101
Therapeutic Area: Neurology Product Name: ENX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nan Fung Life Sciences
Deal Size: $64.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 03, 2021
Details:
The acquisition strengthens Engrail’s presence in the GABA-A space and provides a strong platform for initiation of clinical trials with multiple assets in 2021.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Engrail Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 02, 2021
Details:
The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.
Lead Product(s): ENX-101
Therapeutic Area: Neurology Product Name: ENX-101
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Nan Fung Life Sciences
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
